AdAlta Ltd lists on the ASX | BioMelbourne Network

Melbourne-based company, and BioMelbourne Network Member, AdAlta Limited has listed on the ASX.

AdAlta is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known as i-bodies, for treating a wide range of human diseases.i-bodies are a human analogue of the antigen binding domain of the shark antibody; they combine the high target specificity and affinity advantages of antibodies with the beneficial features of small molecule drugs.

The Company’s lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need. AdAlta intends to continue further discovery and development activities directed towards other disease targets for in-house development or partnering.

Home

News & opinion

Member Directory

Events

CLICK HERE TO SUBSCRIBE TO OUR NEWSLETTER

BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia’s first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.

We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.